Product
Disease modifying treatment
Aliases
Disease modifying treatment (DMT)
1 clinical trial
1 indication
Indication
Relapsing-Remitting Multiple SclerosisClinical trial
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light Levels (SOSTOS)Status: Recruiting, Estimated PCD: 2026-02-20